Speaker: Tanya O'Brien, BSc Pharm
Tanya graduated from Memorial University of Newfoundland School of Pharmacy in 2001. Tanya began her hospital pharmacy career in 2002 at the teaching hospital the Health Sciences Centre in St. John’s, Newfoundland. She had her first clinical role in Infectious Diseases and still uses these skills in her current role as Clinical Pharmacist II in Intensive Care/Cardiovascular Surgery Intensive Care. Her ICU career goes back to 2006 and Cardiovascular Surgery was added to the mix in 2019. Tanya has contributed to the local CSHP NL Branch Executive as Treasurer for 2 terms from 2005-2009. She is also a Professional Associate of MUN School of Pharmacy, precepting students and residents during their rotations in her clinical area. Tanya is a lifelong learner and is committed to sharing her knowledge.
- Describe the mechanism of action of Sodium-glucose transport protein 2 (SGLT2) inhibitors.
- State the evidence for SGLT2 inhibitors in Cardiovascular (CV) patients.
- Identify the pathophysiology of euglycemic diabetic ketoacidosis (DKA) with SGLT2 inhibitors.
- Apply various health agency's recommendations for SGLT2 inhibitors to patients in the hospital setting.
- Illustrate some cases of eDKA at Eastern Health and apply various health agency's recommendations for SGLT2 inhibitors in the hospital setting.
- Summarize appropriate management of hospitalized patients on SGLT2 inhibitors
Join the live webinar May 31, 2022 from 1:00 pm to 2:00 pm ET
Zoom links will be sent the day before the webinar